N,N’-Bis(benzyloxycarbonyl)-1H-pyrazole-1-carboxamidine

We are N,N’-Bis(benzyloxycarbonyl)-1H-pyrazole-1-carboxamidine CAS:152120-55-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:N,N'-Bis(benzyloxycarbonyl)-1H-pyrazole-1-carboxamidine
CAS.NO:152120-55-3
Synonyms:N,N'-Bis(carbobenzoxy)-1H-pyrazole-1-carboxamidine;Pyrazol(Z)2
Molecular Formula:C20H18N4O4
Molecular Weight:378.38100
 
Physical and Chemical Properties:
Density:1.25;
Melting point:90-96oC;
Boiling point:146oC;
Flash point:51oC;
Index of Refraction:1.611;
 
HS Code: 2933199090
UN No.: UN1993
Hazard class: 3 categories 
Packing level: Class III
 
Specification:
Appearance:Off-white to white crystalline powder
Purity(HPLC):≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:As a condensation reagent
 

N,N'-Bis(benzyloxycarbonyl)-1H-pyrazole-1-carboxamidine


Related News: Pharmaceutical intermediates: chemical raw materials or chemical products used in the process of pharmaceutical synthesis, are intermediate products in the process of producing APIs, and can be further processed into APIs.5-Bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine Most foreign drugmakers offered Beijing the lowest prices globally in a recent round of negotiations in order to get some of their new products included in national insurance program, a move that will help them gain access to more patients in less-affluent cities, officials said on Thursday.21724-83-4 The drug review center will establish a registration platform and database for APIs, pharmaceutical excipients and pharmaceutical packaging materials, which means that the domestic drug substance DMF system is expected to be gradually implemented.3-aminopropanol CAS:156-87-6 This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?The company’s short-term plan is to move from a purely chemical intermediate manufacturer to a formula active material supplier, and its long-term goal is to become a solution provider in the selected segment. In the future, this business is expected to become a new growth point for the company’s profit.

Related Products
Product Name
7-chloro-N-(3-chloro-4-fluorophenyl)-6-nitroquinazolin-4-amine View Details
2,5-Dibromopyridine View Details
1-Bromo-2,3-difluorobenzene View Details
4-(Difluoromethoxy)benzenesulfonamide manufacturer chloroethane manufacturer (Diacetoxyiodo)benzene manufacturer 2-FLUORO-6-METHOXYBENZOIC ACID manufacturer 1-Bromo-3-iodobenzene manufacturer